In the world of weight loss medications, the rise of GLP-1 drugs has been nothing short of revolutionary. But with this popularity comes a critical question: Is it safe to pursue these treatments through telehealth companies? The story of Leslie Gammon, a North Carolina woman who suffered a frightening GLP-1 overdose, sheds light on the potential risks and the need for greater oversight. This incident, while concerning, is just the tip of the iceberg when it comes to the safety implications of these drugs, especially when accessed via telehealth.
The GLP-1 Boom and the Risks Involved
GLP-1 drugs, such as Wegovy and Zepbound, have become increasingly popular for weight loss. According to Gallup, approximately 11% of U.S. adults now report taking GLP-1s to lose weight, a significant increase from previous years. This surge in popularity is partly due to the convenience and accessibility offered by telehealth companies. However, the ease of access may come at a cost to patient safety.
The National Poison Data System from America's Poison Centers reports a staggering 1,500% increase in calls related to GLP-1 overdoses and side effects from 2019 to 2025. This alarming trend highlights the potential dangers of these drugs, especially when compounded and prescribed by telehealth companies. Compounded GLP-1 drugs, which are not reviewed by the FDA for safety, can be particularly risky. Patients may accidentally take 10 times the recommended dose due to confusing measurement units, leading to severe side effects and even hospitalization.
The Case of Leslie Gammon
Leslie Gammon's experience is a stark reminder of the risks involved. She turned to two different telehealth companies to obtain GLP-1 medication for weight loss during menopause. The first company provided excellent service, with phone calls and Zoom sessions with a doctor, resulting in significant weight loss. However, when she switched to another telehealth company, Amble, the communication shifted to email, and the experience took a turn for the worse.
After two weeks of using the compounded GLP-1 drug, Gammon didn't notice any reduction in her hunger. She contacted the doctor, who instructed her to inject five times more of the drug than she was previously taking. This sudden increase in dosage, without proper oversight, led to a severe overdose. Gammon spent three days in the hospital, suffering from violent vomiting and dehydration. This experience left her with a $9,000 hospital bill and a lasting impression of the risks associated with compounded GLP-1 drugs.
The Need for Greater Oversight
The incident with Leslie Gammon raises important questions about the oversight and safety measures in place for telehealth companies prescribing GLP-1 drugs. Dr. Fatima Syed, an associate professor of medicine at Duke University, emphasizes that obesity weight management requires clinical oversight, and a simple click in a text or email may not be sufficient. Patients need to trust that there's a system in place to protect them, and this includes clear communication and follow-up care.
The Alliance for Compounded Pharmacies has called for stronger oversight and transparency in the compounding process, especially as the demand for GLP-1 medications increases. Both Novo Nordisk and Eli Lilly, the makers of brand-name GLP-1 drugs, have expressed concerns about the safety of mass-compounded knockoffs. These compounded drugs, often offered by telehealth companies, can be risky, ineffective, or even dangerous.
Conclusion: A Call for Greater Awareness and Regulation
The story of Leslie Gammon serves as a wake-up call for both patients and healthcare providers. While telehealth companies offer convenience, the potential risks associated with GLP-1 drugs, especially compounded versions, cannot be ignored. Patients should be aware of the importance of clear communication and follow-up care when pursuing these treatments. Healthcare providers, meanwhile, must advocate for stronger oversight and regulation to ensure patient safety.
In my opinion, the rise of GLP-1 drugs for weight loss is a double-edged sword. While they offer a promising solution for many, the risks associated with compounded versions, especially when accessed via telehealth, cannot be overlooked. It's time for a broader conversation about the safety and regulation of these medications, with a focus on patient well-being and informed decision-making.
